Immuno-Oncology | Specialty

Immunotherapy Makes Comeback in RCC, But Challenges Remain

December 6th 2016

Robert G. Uzzo, MD, discusses the promise of immunotherapies as well as the challenges with using them across different indications in renal cell carcinoma.

Immunotherapy Rapidly Redefining Treatment in Bladder Cancer

December 6th 2016

Daniel P. Petrylak, MD, sheds light on the emerging roles of both immunotherapy and targeted agents in the treatment of patients with bladder cancer.

Improved PFS, ORR With Frontline Nivolumab and Nivolumab/Ipilimumab Combo in NSCLC

December 6th 2016

Findings from an efficacy update of patients participating in a study in the CheckMate series revealed that first-line nivolumab (Opdivo) demonstrated activity in advanced non–small cell lung cancer, and the addition of ipilimumab (Yervoy) resulted in enhanced activity, specifically in prolonged progression-free survival and higher objective response rates.

Early Results Positive for First-Line Avelumab in NSCLC

December 6th 2016

Treatment with first-line avelumab yielded promising clinical benefit and durable antitumor activity in patients with advanced non–small cell lung cancer.

Prognostic Factors Plus PD-L1 Expression May Be Linked With Early Survival Risk for Nivolumab in NSCLC

December 5th 2016

While treatment with nivolumab (Opdivo) significantly improved overall survival over docetaxel in patients with advanced non–small cell lung cancer in the CheckMate-057 trial, an analysis of deaths occurring within 3 months of initiation of therapy showed numerically more deaths in the nivolumab arm.

Pembrolizumab Combo Highly Effective for Heavily Pretreated Myeloma

December 5th 2016

Treatment with the combination of pembrolizumab, pomalidomide, and dexamethasone demonstrated promising durable efficacy and a tolerable safety profile for patients with relapsed/refractory multiple myeloma.

Nivolumab/Ibrutinib Combo Shows Promise for Richter Transformation

December 3rd 2016

Treatment with the combination of nivolumab and ibrutinib showed encouraging activity and safety in a small phase II study of patients with chronic lymphocytic leukemia and Richter transformation.

Immuno Combos Gain Steam in Blood Cancers

December 2nd 2016

Checkpoint blockade immunotherapies that have moved quickly from the development stage to clinical use in a range of solid tumors are also being explored in hematologic malignancies.

Dr. Antonia on Emerging Immunotherapies in Lung Cancer

December 2nd 2016

Scott J. Antonia, MD, PhD, chair of the Department of Thoracic Oncology at Moffit Cancer Center, discusses immunotherapies that are emerging in the field of lung cancer.

FDA Grants Pembrolizumab Priority Review for Hodgkin Lymphoma

December 1st 2016

The FDA has granted a priority review to a supplemental biologics license application for pembrolizumab for use as a treatment for patients with refractory classical Hodgkin lymphoma or those who have relapsed after ≥3 lines of therapy,

Immunotherapy Combos on Horizon in First-Line RCC

December 1st 2016

Immunotherapy combinations have significant potential as treatment for patients with renal cell carcinoma.

Expert Assesses Rapidly Expanding Therapeutic Options in RCC

December 1st 2016

The treatment landscape of renal cell carcinoma is changing at a remarkably fast pace.

Future of Genetic Testing and Treatment in Prostate Cancer

December 1st 2016

PARP Inhibitors in BRCA1/2-mutated Patients in Prostate Cancer

December 1st 2016

Identifying Bone Progression in Metastatic Prostate Cancer and Treatment Options

December 1st 2016

Immunotherapy and the Abscopal Effect in Treating Metastatic Prostate Cancer

December 1st 2016

Radium-223 Alone and with Other Agents for Prostate Cancer

December 1st 2016

FDA-approved Indications for Treatment Versus Use in Current Clinical Trials

December 1st 2016

Clinical Trials in Nonmetastatic Castration-Resistant Prostate Cancer

December 1st 2016

Challenges in Treating Nonmetastatic Castration-Resistant Prostate Cancer

December 1st 2016